Page last updated: 2024-08-24

lisofylline and Hyperglycemia, Postprandial

lisofylline has been researched along with Hyperglycemia, Postprandial in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bolick, DT; Hatley, ME; Hedrick, CC; Nadler, JL; Srinivasan, S1

Other Studies

1 other study(ies) available for lisofylline and Hyperglycemia, Postprandial

ArticleYear
Lisofylline, a novel antiinflammatory compound, protects mesangial cells from hyperglycemia- and angiotensin II-mediated extracellular matrix deposition.
    Endocrinology, 2003, Volume: 144, Issue:12

    Topics: Angiotensin II; Anti-Inflammatory Agents, Non-Steroidal; Cells, Cultured; Connective Tissue Growth Factor; Cyclic AMP Response Element-Binding Protein; Extracellular Matrix; Extracellular Matrix Proteins; Fibronectins; Gene Expression; Glomerular Mesangium; Glucose; Humans; Hyperglycemia; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Pentoxifylline; Phosphorylation; Transforming Growth Factor beta; Vasoconstrictor Agents

2003